What is HC Wainwright’s Estimate for NRSN FY2026 Earnings?

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) – Stock analysts at HC Wainwright issued their FY2026 earnings per share estimates for NeuroSense Therapeutics in a research note issued on Thursday, September 3rd. HC Wainwright analyst L. Egana-Gorrono anticipates that the company will post earnings per share of ($0.37) for the year. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for NeuroSense Therapeutics’ current full-year earnings is ($0.38) per share. HC Wainwright also issued estimates for NeuroSense Therapeutics’ FY2027 earnings at ($0.53) EPS, FY2028 earnings at ($0.68) EPS, FY2029 earnings at ($0.75) EPS and FY2030 earnings at $0.93 EPS.

Separately, Weiss Ratings downgraded shares of NeuroSense Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, NeuroSense Therapeutics has an average rating of “Moderate Buy” and an average price target of $8.50.

NeuroSense Therapeutics Stock Performance

NASDAQ NRSN opened at $0.51 on Monday. NeuroSense Therapeutics has a twelve month low of $0.25 and a twelve month high of $1.98. The stock has a market capitalization of $19.29 million, a PE ratio of -0.95 and a beta of 1.60. The stock has a 50-day simple moving average of $0.55 and a 200 day simple moving average of $0.71.

Hedge Funds Weigh In On NeuroSense Therapeutics

Hedge funds have recently modified their holdings of the stock. Yorkville Advisors Global LP acquired a new stake in NeuroSense Therapeutics in the 2nd quarter valued at $56,160. Squarepoint Ops LLC lifted its holdings in shares of NeuroSense Therapeutics by 91.0% during the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after acquiring an additional 45,450 shares during the period. Jane Street Group LLC acquired a new stake in shares of NeuroSense Therapeutics in the 2nd quarter valued at $54,000. Finally, Two Sigma Investments LP acquired a new stake in shares of NeuroSense Therapeutics in the 3rd quarter valued at $26,000. 1.04% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at NeuroSense Therapeutics

In other NeuroSense Therapeutics news, CEO Alon Ben-Noon purchased 250,000 shares of the business’s stock in a transaction on Tuesday, June 16th. The stock was purchased at an average price of $0.80 per share, for a total transaction of $200,000.00. Following the completion of the purchase, the chief executive officer directly owned 4,534,233 shares in the company, valued at approximately $3,627,386.40. This trade represents a 5.84% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Or Eisenberg acquired 250,000 shares of the firm’s stock in a transaction on Tuesday, June 16th. The shares were bought at an average cost of $0.80 per share, for a total transaction of $200,000.00. Following the completion of the acquisition, the chief financial officer directly owned 1,504,050 shares of the company’s stock, valued at approximately $1,203,240. This represents a 19.94% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 27.40% of the company’s stock.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.